ANXA10 and pancreatic ductal adenocarcinoma: Of special interest, high ANXA10 expression was reported as an independent poor prognostic biomarker in lung adenocarcinoma (Yumura et al., 2022), glioblastoma multiforme (Xu et al., 2021), serous epithelial ovarian cancer (Wang et al., 2019), pancreatic ductal adenocarcinoma (Ishikawa et al., 2022b), small bowel adenocarcinoma (Ishikawa et al., 2021) and papillary thyroid cancer (Liu X. et al., 2021).